PharmaLogic Holdings Corp. announced on November 9, 2026, a definitive agreement to acquire the CDMO business and Springfield, New Jersey manufacturing facility from Lantheus Holdings, Inc. (NASDAQ:LNTH), with financial terms not disclosed.
Key Highlights
- Definitive agreement signed: PharmaLogic will acquire Lantheus' CDMO business and its Springfield, New Jersey manufacturing facility; financial terms were not disclosed.
- Long-term supply agreement included: Upon closing, Agilera, PharmaLogic's therapeutic CDMO franchise, will manufacture lutetium Lu 177 dotatate for Lantheus under a long-term supply arrangement.
- Transatlantic platform: According to the announcement, the acquisition positions PharmaLogic as the first therapeutic CDMO to offer a transatlantic platform for radioligand therapies.
- Global supply reach: PharmaLogic currently supplies an alpha therapy to more than 30 countries, and Agilera brings more than 15 years of experience supporting radioligand therapy development and commercial launch.
- Regulatory conditions: The transaction is subject to applicable regulatory review and the satisfaction of other customary closing conditions.
- Advisors named: Leerink Partners and Goodwin Procter LLP advised PharmaLogic; Solomon Partners Securities LLC and Covington and Burling LLP advised Lantheus.
PharmaLogic Expands Radiopharmaceutical Therapeutic Capacity With Lantheus Springfield Facility
According to the filing, PharmaLogic Holdings Corp. describes itself as "the only independent contract development and manufacturing organization (CDMO) of scale dedicated exclusively to radiopharmaceuticals in North America," operating more than 45 facilities across the U.S., Puerto Rico, Canada, and Norway. The company serves both diagnostic and therapeutic segments, and the therapeutic franchise, Agilera, holds what PharmaLogic characterizes as a unique position as the world's only cGMP-compliant CDMO currently manufacturing and distributing a commercial radiopharmaceutical therapeutic to more than 30 countries.
The Springfield, New Jersey facility being acquired from Lantheus is described in the announcement as "a state-of-the-art radiopharmaceutical manufacturing site with a proven track record in theranostic manufacturing, research and clinical development." The skilled team at that site is expected to join Agilera upon closing. PharmaLogic's CEO Etienne Montagut stated, "This acquisition strengthens Agilera's unique capabilities in radioligand therapies and expands our capacity in the U.S." Mary Anne Heino, Executive Chairperson and CEO of Lantheus, cited the companies' "long-standing relationship," noting that PharmaLogic "has been an important manufacturing partner for our PET products."
Lantheus, which the filing describes as "the leading radiopharmaceutical-focused company" with 70 years of radiopharmaceutical solutions and headquarters in Massachusetts, retains a commercial interest through the long-term supply agreement under which Agilera will manufacture lutetium Lu 177 dotatate. The parties disclosed they will continue to operate independently until the transaction closes, pending regulatory review and customary closing conditions. No timeline for closing was stated in the announcement.
What Was Disclosed
PharmaLogic Holdings Corp. disclosed a definitive agreement to acquire Lantheus' (NASDAQ:LNTH) CDMO business and Springfield, New Jersey facility, including a long-term lutetium Lu 177 dotatate supply agreement. Financial terms were not disclosed. The deal remains subject to regulatory review and customary closing conditions.




Please wait processing your request...